Drug Profile
ERC 124
Alternative Names: Endometrial blood stem cell therapy - Intrexon; Endometrial regenerative cells; ERC-124Latest Information Update: 07 Feb 2020
Price :
$50
*
At a glance
- Originator MediStem Laboratories; Yale University
- Developer Brigham and Womens Hospital; ERCell LLC; Intrexon Corporation; Yale University
- Class Heart failure therapies; Stem cell therapies; Vascular disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Brain injuries; Chronic limb-threatening ischemia; Heart failure; Peripheral vascular disorders; Type 1 diabetes mellitus
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 03 Oct 2015 No recent reports of development identified - Clinical-Phase-Unknown for Chronic limb threatening ischemia in China (IM)
- 03 Oct 2015 No recent reports of development identified - Phase-II for Heart failure in Russia (Intracoronary)